CSI Market
Sign In | Register

Gyre Therapeutics Inc (GYRE) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access GYRE Annual Cash Flow →
Cash flow patterns shown here provide context for understanding Gyre Therapeutics Inc's ability to sustain operations and capital deployment.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-57.66
Depreciation & amortization2.16
Amortization of Other Assets0.35
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.92
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.02
Share-based Compensation4.66
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.22
Increase Decrease In Receivables From Collaborations-
Non Cash Interest On Convertible Debt-
Investment Income Amortization Of Premium-
Increase Decrease In Operating Lease Liability And Right Of Use Asset-
Change In Fair Value Of Long Term Receivables-
Acquired In Process Research And Development-
Equity Gain Loss Of Unconsolidated Affiliates0.02
Increase Decrease In Accounts And Notes Receivables-
Net Proceeds From Cvr Liability Settlement-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-9.47
Increase (Decrease) in Accounts Payable4.80
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.18
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.07
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net-11.95
Payments for (Proceeds from) Other Operating Activities54.76
Discontinued operations0.00
Net Cash flow from Operating Activities-13.55
Investing Activities
Capital Expenditures-1.47
Sale of Capital Items0.01
Payments to Acquire Short-term Investments13.07
Short-term Investments Acq.-2.03
Real Estate Investments0.00
Proceeds From Reverse Merger-
Payments To Acquire Short Term And Long Investments-
Payment Of Transaction Costs In Connection With Sale Of Complement Portfolio-
Payment Of Transaction Costs In Connection With Sale Of Legacy Rare Bleeding Disorder Program-
Cash Paid For Acquisition Costs-
Payment For Equity Method Investment-
Payments to Acquire Restricted Certificates of Deposit-15.88
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale and Maturity of Other Investments13.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities6.70
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.22
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.21
Proceeds From Issuance Of Preferred Stock Common Stock And Warrants For Follow On Offering Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock For Secondary Public Offering Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock From Stock Grants And Option Exercises-
Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock From E S P P Purchases And Stock Option Exercises-
Proceeds From Issuance Of Common Stock From Stock Grants-
Acquisition Costs In Due To Related Parties-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Proceeds From Exercise Of Stock Options Included In Other Receivable-
Purchase Of Property And Equipment Included In Accounts Payable-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations37.07
Convertible Preferred Stock Conversion-
Non Cash Acquisition Of Property And Equipment Through Prepaid Conversion-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-15.00
Total Cash Flow-5.91
4 historic quarters locked

Sign in to unlock the full Gyre Therapeutics Inc cash flow history.

Sign In Create Free Account

About Gyre Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-340448

Figures are derived from filed reports and may be restated. Historical data is subject to revision.